Literature DB >> 20853084

[Priority setting in healthcare. What can Germany learn from other countries?].

R Busse1, C Hoffmann.   

Abstract

Internationally, priority setting has been debated since the late 1980s, partly only regarding underlying principles, but partly with real implications for the benefit basket. Whereas all approaches reviewed (Norway, Sweden, Denmark, Oregon, The Netherlands, New Zealand) are convincing, those that relied on public consensus and left the priority-setting principles to the discretion of individual healthcare professionals had no effect as early prioritization efforts in the Scandinavian countries show. Prioritization approaches that have relied on concrete lists of indication-treatment pairs (for example, in the U.S. state of Oregon across all areas of care and in Sweden the form of guidelines within indication groups) have led to changes but not always to the expected results: expenditure was only moderately reduced but the provision of care has become more transparent. Regardless of the differences between the various countries, they have several things in common: a heated public debate, a very long implementation timeline, and the lack of a (much feared) prioritization according to age, gender, or social status. Recently, priority setting has been seen as complementary to health technology assessments, guidelines, and quality assurance, all with their own focuses.

Mesh:

Year:  2010        PMID: 20853084     DOI: 10.1007/s00103-010-1115-y

Source DB:  PubMed          Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz        ISSN: 1436-9990            Impact factor:   1.513


  2 in total

1.  Priority setting in health care: trends and models from Scandinavian experiences.

Authors:  Bjørn Hofmann
Journal:  Med Health Care Philos       Date:  2013-08

2.  Who Shall Not Be Treated: Public Attitudes on Setting Health Care Priorities by Person-Based Criteria in 28 Nations.

Authors:  Jana Rogge; Bernhard Kittel
Journal:  PLoS One       Date:  2016-06-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.